항응고제 시장 보고서 : 약제 클래스별, 투여 경로, 유통 채널, 용도, 지역별(2026-2034년)

The global anticoagulants market size reached USD 48.7 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 97.7 Billion by 2034, exhibiting a growth rate (CAGR) of 7.80% during 2026-2034. The rising cases of thrombotic disorders, sedentary lifestyles, and the improving healthcare sector represent some of the key factors driving the market.

Anticoagulants are medicines that prevent the formation of blood clots and reduce the chances of developing severe conditions, such as strokes and heart attacks. They assist in treating existing blood clots that resist the flow of blood through vessels and prevent them from getting larger and reducing the risk of serious complications. They are available in different strengths and colors and as oral, such as tablets and capsules, and injectable variants. At present, direct oral anticoagulants (DOAc) are increasingly being prescribed on account of their ease of use and lack of need for routine monitoring.

Anticoagulants Market Trends:

The growing geriatric population and increasing prevalence of human immunodeficiency virus (HIV), lyme disease, obesity, hepatitis C, chronic inflammation, and cardiovascular disorders across the globe represent one of the key factors positively influencing the market across the globe. In addition, rising cases of thrombotic disorders, such as pulmonary embolism (PE), on account of sedentary lifestyles and hectic work schedules are inducing the growth of heart-related diseases worldwide. Moreover, extended sitting, smoking, trauma, blood disorders, and autoimmune diseases are increasing the risk of blood clotting in different parts of the body, which, in turn, is catalyzing the demand for anticoagulants. Apart from this, increasing advancements in research and development (R&D) activities in drug discovery and the integration of advanced technologies, such as artificial intelligence (AI) and machine learning (ML) to analyze large amounts of data, identify potential drug candidates and develop a new drug is fueling the market growth. In line with this, healthcare providers are focusing on personalizing anticoagulant therapy for individual patients based on their genetic and clinical data. AI assists in identifying the most effective dose and type of anticoagulant for the patient, which, in turn, reduces the risk of complications and improves outcomes. Furthermore, favorable initiatives by non-profitable organizations to promote awareness about cardiovascular health and the growing partnerships between governments of various countries and public health agencies to prevent heart disease and strokes are propelling the growth of the market worldwide. Other factors like the burgeoning healthcare sector and increasing affordability and accessibility of drugs are stimulating the growth of the market.

Key Market Segmentation:

The publisher provides an analysis of the key trends in each sub-segment of the global anticoagulants market report, along with forecasts at the global, regional and country level from 2026-2034. Our report has categorized the market based on drug class, route of administration, distribution channel and application.

Drug Class Insights:

• Novel Oral Anticoagulants (NOACs)
• Heparin and Low Molecular Weight Heparin (LMWH)
• Vitamin K Antagonist
• Others

Route of Administration Insights:

• Oral Anticoagulant
• Injectable Anticoagulant

Distribution Channel Insights:

• Hospital Pharmacies
• Retail Pharmacies
• Online Stores
• Others

Application Insights:

• Atrial Fibrillation and Heart Attack
• Stroke
• Deep Vein Thrombosis (DVT)
• Pulmonary Embolism (PE)
• Others

Regional Insights:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for anticoagulants. Some of the factors driving the North America anticoagulants market included the increasing prevalence of thrombotic disorders, developed healthcare sector, ongoing research and development (R&D) activities in drug discovery etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global anticoagulants market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Alexion Pharmaceuticals Inc, Aspen Holdings, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Dr. Reddy's Laboratories Ltd, GlaxoSmithKline plc, Johnson & Johnson Private Limited, Pfizer Inc., Sanofi, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report

Key Questions Answered in This Report

• 1.What was the size of the global anticoagulants market in 2025?
• 2.What is the expected growth rate of the global anticoagulants market during 2026-2034?
• 3.What are the key factors driving the global anticoagulants market?
• 4.What has been the impact of COVID-19 on the global anticoagulants market?
• 5.What is the breakup of the global anticoagulants market based on the drug class?
• 6.What is the breakup of the global anticoagulants market based on the route of administration?
• 7.What is the breakup of the global anticoagulants market based on the distribution channel?
• 8.What is the breakup of the global anticoagulants market based on the application?
• 9.What are the key regions in the global anticoagulants market?
• 10.Who are the key players/companies in the global anticoagulants market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Anticoagulants Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Drug Class

• 6.1 Novel Oral Anticoagulants (NOACs)
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Heparin and Low Molecular Weight Heparin (LMWH)
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Vitamin K Antagonist
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Others
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Route of Administration

• 7.1 Oral Anticoagulant
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Injectable Anticoagulant
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

• 8.1 Hospital Pharmacies
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Retail Pharmacies
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Online Stores
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Application

• 9.1 Atrial Fibrillation and Heart Attack
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Stroke
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Deep Vein Thrombosis (DVT)
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Pulmonary Embolism (PE)
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast
• 9.5 Others
  • 9.5.1 Market Trends
  • 9.5.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Alexion Pharmaceuticals Inc
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Aspen Holdings
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 Bayer AG
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 Boehringer Ingelheim International GmbH
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
  • 15.3.5 Bristol-Myers Squibb Company
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
    • 15.3.5.4 SWOT Analysis
  • 15.3.6 Daiichi Sankyo Company Limited
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 Financials
    • 15.3.6.4 SWOT Analysis
  • 15.3.7 Dr. Reddy's Laboratories Ltd
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
    • 15.3.7.4 SWOT Analysis
  • 15.3.8 GlaxoSmithKline plc
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Johnson & Johnson Private Limited
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 Pfizer Inc.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis
  • 15.3.11 Sanofi
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
    • 15.3.11.4 SWOT Analysis